<DOC>
	<DOCNO>NCT01329627</DOCNO>
	<brief_summary>The purpose study determine whether weekly paclitaxel follow weekly doxorubicin plus daily oral cyclophosphamide without granulocyte colony-stimulating factor ( G-CSF ) feasible treatment locally advance HER2-negative breast cancer .</brief_summary>
	<brief_title>Feasibility Study Metronomic Chemotherapy Locally Advanced HER2-Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Locally advanced breast cancer diagnose guide core biopsy T &gt; 2 cm ( N ) , T node positive ( needle biopsy require ) Nonmetastatic disease assess compute tomography bone scintigraphy Histological grade 2 Ki67 &gt; 15 % Histological grade 3 Any triple negative ( TN ) Inflammatory breast cancer ( IBC ) Normal leave ventricular ejection fraction ( LVEF ) HER2negative disease Another malignancy within last 5 year ( except curatively treat skin carcinoma , situ cervix carcinoma , situ ductal carcinoma breast , situ lobular carcinoma breast ) Clinically significant comorbidities cardiovascular disease , chronic obstructive pulmonary disease ( COPD ) , renal liver failure , psychiatric disorder LVEF value institutional limit normal Predominant lobular carcinoma histology Grade 1 tumor Detected suspicious distant metastasis Neutrophils le 1,500/µL , platelet le 100,000/µL , hemoglobin le 10 g/dL , AST 2.5x upper limit normal ( ULN ) , total bilirubin ULN , alkaline phosphatase 1.5x ULN Male sex HER2positive breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>